An Ocular Formulation & a Method for its Preparation (Patent granted:351437)

An Ocular Formulation & a Method for its Preparation (Patent granted:351437)

100,000.00 (Incl. of GST)

Purpose
Control age-related macular degeneration and diabetic retinopathy by topical
application of atorvastatin (ATS) using solid lipid nanoparticles (SLN) technology

by Dr. Indu Pal Kaur | Contact vendor
Sorry, this product is not refundable.

An Ocular Formulation & a Method for its Preparation

Specifications of An Ocular Formulation
• Prolonged residence, up to 7 h of ATS-SLNs in eyes.
• Three-tier (in vitro, ex vivo, and in vivo) ocular safety, improved stability (13.62 times)
including photostability was established.
Applications of An Ocular Formulation
• Special application for treatment of posterior eye diseases including AMD and
diabetic retinopathy which are otherwise catered to by the invasive routes of
administration.
• ATS-SLNs are 8 and 12 times more bioavailable in aqueous and vitreous humor,
respectively.

Spread the love

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Need Help? Contact Us Leave Feedback

Categories: , ,

Tags: , , , , ,